Newsletter Life Sciences Voice Top Five Newsletter February 2023

Life Sciences Voice Top Five Newsletter February 2023


This week we take a look at AI helping doctors with administrative tasks, a study that found that autism can be detected in infants, a possible new therapy for depression and other top news!

Doximity aims to help doctors with ChatGPT Tool Beta Version

ChatGPT is an artificial intelligence (AI) language model created by OpenAI. Recently the tool gained a lot of attention and fame for its possible applications in education and healthcare. A beta version was launched by Doximity that is specifically made to help doctors with administrative tasks that consist of but are not limited to writing and faxing objection letters and pre-authorizations to insurance companies. Jeffrey Tangey, CEO of Doximity announced the beta version called on Thursday. To read more, click here. 

 New study reveals potential autism detection in infants

A study at Duke University proposes that there can be autism detection within the first month of birth. In general terms, autism is a neurodevelopmental disorder that can be noticed by limited cognitive ability and patterns in behavior. There is also usually trouble with social interactions. Normally the children are diagnosed aged between three and four. According to Marc Weisskopf, a well-known epidemiologist, this gives confidence to the theory that states autism can be traced back to pre-birth. Therapy can be started sooner if the warning flags can be known at an early age. To read more, click here.

300 employees laid off from Amgen’s U.S. office

Amgen’s corporate spokeswoman said that there have been organizational changes recently due to which the company has let go of 300 employees (1.2% of the total employees) from the commercial sector in the States. As of 2021, the company employed nearly 24,200 employees in 50 countries according to Amgen’s regulatory filing with the SEC (U.S. Securities and Exchange Commission). The new upsurge in layoffs has seen big tech organizations and Wall Street entities at the vanguard. To read more, click here.

Primary Progressive MS confirmed as a distinct disease in a new study

MS, or Multiple sclerosis, has been widely studied and its rarer and more severe form has been believed to be a completely different illness by researchers. A new study has verified this by using a mouse model which is more precise. The initial primary progressive MS (PPMS) model was shaped by researchers at Tisch MS Research Center in New York. It revealed that primary progressive MS had an isolated pathology compared to other types of MS. The revelations made by the researchers show that PPMS needs to be treated differently. To read more, click here.

Depression therapy approval expected by Biogen and Sage

The decision regarding the approval of zuranolone will be made by the FDA in August this year. The FDA will also decide whether to grant priority review for postpartum depression (PPD) and major depressive disorder (MDD). The final filings for both ailments were completed in 2022. Sage’s neuroactive steroid is supposed to be used episodically. If approved, it would be the first depression medicine on the market with a 14 days treatment cycle. This approval of the application is the first win for Sage since 2019 when it faced disappointment in zuranolone’s phase 3 trial in MDD. After joining hands with Biogen in 2020, the plan was to complete the R&D goal that was originally planned to bring zuranolone to market in 2022. To read more, click here. 

Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you